Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Health virtual twins for the personalised management of stroke related to atrial fibrillation

Project description

Advances in atrial fibrillation-related care

Atrial fibrillation (AF) stands as the most prevalent heart arrhythmia globally, fuelling life-threatening complications and substantial economic strain. In Europe, AF-induced strokes rank among the leading causes of mortality and disability, with patients facing a fivefold increase in ischaemic stroke risk. Recovery from AF-related strokes often proves inadequate, leading to profound disability and diminished quality of life. In this context, the EU-funded TARGET project will introduce personalised, multi-scale computational models and decision aids for AF-related stroke. By integrating data from healthy states to disease progression, TARGET aims to revolutionise prevention, acute management and rehabilitation. Patient-centric and backed by industry expertise, the project promises swift adoption of innovative technologies. Through simulation trials, TARGET strives for tangible clinical benefits.

Objective

Atrial fibrillation (AF) is the most common heart arrhythmia worldwide, leading to life-limiting complications, high financial burden and significant resource utilisation. In Europe, stroke as a debilitating complication of AF, is amongst the commonest causes of death and the leading cause of disability. AF patients have a 5-fold increased risk for ischaemic stroke. Functional recovery from AF-related stroke (AFRS) is often unsatisfactory, leading to severe disability, reduced quality of life and high mortality.
TARGET’s ambition is to develop novel personalised, integrated, multi-scale computational models (virtual twins) and decision-support tools for the AF-related stroke pathway, starting from the healthy state, pathophysiology and disease onset, progression, treatment and recovery. TARGET aims to help prevent AF and AFRS, optimise acute management and rehabilitation, reduce long-term disability, provide a better quality of life for patients and caregivers, and lower healthcare costs.
We will ensure patients are at the heart of the project, and the association with experienced commercial partners will ensure the swift adoption of TARGET’s novel technologies. New observational data will be collected via 4 carefully designed prospective clinical studies, which will be used to test and validate the personalised tools and the virtual twin models using a clinical trial simulation (virtual/in-silico), to demonstrate evidence of clinically meaningful results.
TARGET will also help consolidate existing mechanistic virtual twin models of the heart, the brain and the neuromusculoskeletal system, enriching these twins to deliver more complex tasks, and supporting research to move towards a more integrated human virtual twin. TARGET represents a milestone project to improve the care and rehabilitation of patients with AF and AFRS, introducing a paradigm shift in risk prediction, diagnosis and management of the disease, and accelerating translational research into practice.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-RIA - HORIZON Research and Innovation Actions

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-HLTH-2023-TOOL-05

See all projects funded under this call

Coordinator

LUNDS UNIVERSITET
Net EU contribution
€ 650 805,00
Address
Paradisgatan 5c
22100 Lund
Sweden
Region
Södra Sverige Sydsverige Skåne län
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 650 805,00

Participants (14)

Partners (5)